FDA Approved: KALETRA — Supplemental Application (AbbVie Inc.)

View source ↗

Summary

The FDA approved AbbVie’s supplemental application for KALETRA (lopinavir/ritonavir), authorizing changes to the product labeling and/or additional indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acquired Immunodeficiency Syndrome
• HIV Infection

Drugs mentioned

• Kaletra (lopinavir)

Snippet

SUPPL AP for KALETRA (LOPINAVIR AND RITONAVIR)